Newsletter | January 7, 2021

01.07.21 -- Cell & Gene Best Of December
 

Hello Cell & Gene readers,

 

I’m happy to bring you December’s most-clicked articles. Enjoy.

 

Erin Harris, editor in chief
Follow me on Twitter
December's Best Featured Editorial
Partly Cloudy And Chance Of COVID-19: Bringing The Umbrellas And Raincoats For Cell And Gene Therapy
By Bruce Levine, Ph.D., Barbara and Edward Netter professor in cancer gene therapy, University of Pennsylvania; president, International Society for Cell & Gene Therapy
The tragic combination of infectiousness and lethality of SARS-CoV-2 and COVID-19 has been the greatest public health emergency of the past 100 years. But there is a way forward through science, discovery, translation, and execution.
COVID-19 And Beyond: Perspectives From A Regulatory Affairs Professional
By Jiwen Zhang, VP, Regulatory Affairs, Passage Bio

COVID-19 has significantly impacted our daily life, work, and productivity and has manifested social, economic, and cultural issues.
Contingency Planning For Quality In The Cell And Gene Sector Due To COVID-19
By Michael Blackton, VP QA CMC, at Adaptimmune

Maintaining clinical trials during the COVID-19 pandemic has presented quite a challenge for those companies exploring novel therapies.
December's Best Industry Insights
A Brief Introduction To CAR T-Cell Therapy
By Premier Research
With the approvals of tisagenlecleucel (KYMRIAH) and axicabtagene ciloleucel (YESCARTA) last year, CAR T-cell therapies have changed the treatment paradigm for patients with certain hematologic malignancies. This blog breaks down the development of CAR T-cell therapy as well as its advantages and challenges.
Reducing Cost Of Goods For Gene Therapy
By Sudeep Basu, Frost & Sullivan

Frost & Sullivan's Virtual Think Tank brought together leading minds to discuss key challenges and other insights related to reducing the cost of goods (COGs) for gene therapy.
Considerations For Development Of A Platform Lentivirus Harvest Clarification Process For Cell And Gene Therapy
By John Taylor, MilliporeSigma and Luan Truong, WuXi Advanced Therapies

One of the new technologies emerging in the biotech manufacturing market is the use of viral vectors for cell and gene therapy. One commonly used viral vector in this space is lentivirus, due to its robustness to package and deliver target DNA. This work explores a variety of lentivirus harvest clarification options and items for consideration during manufacturing platform development of viral therapy production using suspension cell lines.